Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

Phase 2

Completed

• Conditions: Hypertension

• Registration Number: NCT00160212
• Lead Sponsor: Solvay Pharmaceuticals

Brief Summary

This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-12
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-09
• Study First Posted: 2005-09-12
• Status Verified: 2009-01
• Last Update Submitted: 2009-01-29
• Last Update Posted: 2009-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• sitting office diastolic blood pressure between 90 and 109 mmHg
• office systolic blood pressure between 140 and 179 mmHg
• mean day-time diastolic 24-h ABPM blood pressure >= 85 mmHg inclusive at baseline

Exclusion Criteria

• known secondary hypertension
• decompensated congestive heart failure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (130)

Site 705; 🇦🇺 Bracken Ridge, Australia

Site 706; 🇦🇺 Caboolture, Australia

Site 700; 🇦🇺 Inala, Australia

Site 701; 🇦🇺 Kippa Ring, Australia

Site 702; 🇦🇺 Melbourne, Australia

Site 703; 🇦🇺 Nedlands, Australia

Site 952; 🇧🇬 Haskovo, Bulgaria

Site 955; 🇧🇬 Pleven, Bulgaria

Site 951; 🇧🇬 Plovdiv, Bulgaria

Site 956; 🇧🇬 Plovdiv, Bulgaria

Scroll for more (120 remaining)